Prenetics (PRE) EV/EBITDA Multiple
The price chart for Prenetics Global (PRE) demonstrates a value of 0.00, as the company leads the personalized diagnostics and mass DNA testing segment. Business efficiency is supported by a streamlined system for transporting biomaterials to research centers. Growth relies on the popularization of early oncology detection, while financial stability is ensured by a sufficient volume of free cash flow.
Comprehensive metric breakdowns and analytics for prenetics.com (PRE)
- market price and analyst price targets:
- market capitalization details:
- issuer book value statistics:
- company liabilities and liquidity data:
Debt to Equity Prenetics Global|PRE - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Prenetics|PRE - Company Cumulative Debt|Debt to Book Capitalization Ratio Prenetics Global|PRE - Company Long-Term Indebtedness|Company Short-Term Debts Prenetics|Quick Liquidity Indicator prenetics.com
- business earnings and investment ratios data:
PRE - Profit After Payment of Taxes|Projected Future Earnings Prenetics Global|PRE - Business Payback Period|Forward P/E Multiple Prenetics|PRE - Price/Earnings to Growth Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Prenetics Global|PRE - Operating income before deduction of amortization|Net earnings per share for the last 12 months Prenetics|PRE - Earnings per share for the trailing year|Quarterly EPS earnings growth prenetics.com|PRE - Net earnings per share change in current year|Net earnings per share growth forecast for next year Prenetics Global
Initial company analysis:PRE (Prenetics Global Ltd)
To assess the asset quality of Prenetics Global (PRE), we employ a comprehensive approach to business valuation. The current EV/EBITDA ratio, accounting for debt and amortization at 0.00, reflects the relationship between the company's enterprise value and its operating profit before interest, taxes, depreciation, and amortization. For this personalized medicine leader, this metric enables an evaluation of the scaling efficiency of its DNA services relative to its debt load. While low values indicate undervaluation, they also create a risk of capital stagnation.
Competitor analysis for Prenetics Global
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Agilent Tech A|Total Company Value to Operating Income Before Depreciation Ratio Quest Corp (DGX)|Illumina, Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio exactsciences.com EXAS|Revvity (RVTY) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|BIO - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Anbio Tech|Nordion - Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization QuidelOrtho (QDEL)|OPK (opko.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple CDNA (CareDx Inc)|Maravai LifeSciences Holdings (MRVI) - Company Value to EBITDA|FLGT - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|LAB (Standard BioTools Corp) - Enterprise Value to Operating Income Before Depreciation|CTKB: EV/EBITDA Multiple|Company Value to EBITDA orasure.com (OSUR)|Enterprise Value to EBITDA Ratio XGN|MDXH (MDxHealth S.A.) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple LUCD|Total Company Value to Operating Income Before Depreciation Ratio imdxinc.com|EV/EBITDA Multiple TRIB (Trinity Biotech)|PRPH - Enterprise Value to EBITDA Ratio|AIMD - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Co-Diagnostics Inc CODX|HSCS (Heart Test Laboratories Inc.) - Enterprise Value to EBITDA Ratio|Biomerica Inc - Business Value to Operating Income Before Depreciation|CDIO (Cardio Diagnostics Holdings Inc.) - EV/EBITDA Multiple|ONCO - Enterprise Value to EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Virax Biolabs (VRAX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization BJDX (Bluejay Diagnostics Inc)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Vermillion AWH|Accelerate Diagnostics Inc (AXDX) - Company Value to EBITDA|CENTOGENE, N.V. - EV/EBITDA Multiple|ENZ: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|FRES: EV/EBITDA Multiple|Genetic Technologies Limited (GENE) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization 23andMe Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization PMD
